

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 18:23:24 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus


WOW! I did not know that. Good talking point for press conferences.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 9, 2020 1:13 PM
Subject: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

[by Savannah Koplon](#)

- February 07, 2020
- [Print](#)
- [Email](#)



Richard Whitley, M.D., Distinguished Professor at UAB and principal investigator of the U19 grant

The investigational drug remdesivir, developed through research conducted through the [Antiviral Drug Discovery and Development Center](#), or AD3C, and centered at the [University of Alabama at Birmingham](#), is being used to treat select infected patients in the United States and in China who have been affected by the outbreak of novel coronavirus (2019-nCoV).

UAB was awarded a \$37.5 million, [five-year U19 grant](#) from the [National Institute of Allergy and Infectious Diseases Centers of Excellence for Translational Research](#) to study and develop treatment for high-priority emerging infections. Work has been taking place in earnest to develop drugs for emerging influenza, flaviviruses (dengue, West Nile virus and Zika), coronaviruses that cause SARS and MERS, and alphaviruses such as Venezuelan equine encephalitis virus and chikungunya. The grant is a multi-